Eikon’s EIK1003 selectively inhibits PARP1 with the goal of offering the same efficacy as currently available PARP inhibitors while avoiding the toxicity of those drugs. EIK1003 is in Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback